Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29:2592–2597, 2006

In Table 2 of the above-listed article, data was not aligned properly. The corrected table appears below and is available online at http://dx.doi.org/10.2337/dc06-1373.

Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30:217–223, 2007

The clinical trial registry number for the above-listed article appears incorrectly. The correct clinical trial number is NCT00099918.

Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, Dakshinamurthy KV, Roberts CT Jr, Nagalla SR: Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 30:629–637, 2007

Four authors of the above-listed article have incorrect degree abbreviations listed. The correct abbreviations are Xinfang Lu, MS; Melissa Standley, BS; Patrick Pattee, BS; and Charles T. Roberts, Jr., PhD. All other authors’ degree abbreviations are listed correctly.

Table 2—

Absolute change from baseline to weeks 12 and 52 and study end in blood glucose (primary outcome) and other measures of glucose control

n (% of total at baseline)Baseline (mean ± SD)Measurement (mean ± SD)Change ± SE*P value*
Primary outcome†      
    Week 12      
T/V 104 (87.4) 7.96 ± 2.47 7.62 ± 2.40 −0.29 ± 0.22 <0.001 
L/H 105 (86.8) 7.94 ± 2.50 8.64 ± 2.73 0.72 ± 0.22  
    Week 52      
T/V 89 (74.8) 7.99 ± 2.51 7.83 ± 3.11 −0.11 ± 0.36 <0.001 
L/H 94 (77.7) 7.75 ± 2.41 9.15 ± 4.08 1.49 ± 0.35  
    Study end      
T/V 108 (90.8) 7.98 ± 2.44 7.74 ± 2.98 −0.21 ± 0.36 <0.001 
L/H 107 (88.4) 7.89 ± 2.50 9.32 ± 4.52 1.44 ± 0.36  
Absolute change in blood insulin (pmol/l) measured at 2 h during an OGTT      
    Week 12      
T/V 100 675.91 ± 405.27 706.40 ± 438.22 33.92 ± 42.48 0.037 
L/H 99 631.62 ± 450.20 773.52 ± 510.17 147.67 ± 41.18  
    Week 52      
T/V 83 639.01 ± 382.51 585.77 ± 447.92 −52.14 ± 44.79 0.014 
L/H 86 648.47 ± 460.15 718.29 ± 511.98 90.15 ± 42.88  
    Study end      
T/V 105 672.02 ± 397.71 633.09 ± 456.05 −30.13 ± 38.38 0.025 
L/H 102 633.51 ± 444.43 711.34 ± 497.01 84.86 ± 38.33  
Absolute change in fasting blood glucose (mmol/l) at 0 min during an OGTT      
    Week 12      
T/V 104 5.90 ± 0.89 5.71 ± 0.69 −0.07 ± 0.08 <0.001 
L/H 107 5.77 ± 0.69 6.08 ± 0.89 0.33 ± 0.08  
    Week 52      
T/V 89 5.90 ± 0.87 6.26 ± 1.17 0.36 ± 0.23 0.336 
L/H 95 5.80 ± 0.71 6.46 ± 2.55 0.65 ± 0.22  
    Study end      
T/V 110 5.88 ± 0.88 6.11 ± 1.12 0.24 ± 0.23 0.087 
L/H 110 5.77 ± 0.68 6.57 ± 2.95 0.76 ± 0.22  
Absolute change in A1C (%)      
    Week 12      
T/V 109 5.8 ± 0.6 5.8 ± 0.5 0.0 ± 0.0 <0.001 
L/H 112 5.7 ± 0.5 6.0 ± 0.8 0.3 ± 0.0  
    Week 52      
T/V 94 5.8 ± 0.6 5.9 ± 0.6 0.2 ± 0.1 0.055 
L/H 97 5.7 ± 0.4 6.1 ± 0.9 0.3 ± 0.1  
    Study end      
T/V 115 5.8 ± 0.6 5.9 ± 0.6 0.1 ± 0.1 0.027 
L/H 115 5.7 ± 0.5 6.2 ± 1.4 0.4 ± 0.1  
n (% of total at baseline)Baseline (mean ± SD)Measurement (mean ± SD)Change ± SE*P value*
Primary outcome†      
    Week 12      
T/V 104 (87.4) 7.96 ± 2.47 7.62 ± 2.40 −0.29 ± 0.22 <0.001 
L/H 105 (86.8) 7.94 ± 2.50 8.64 ± 2.73 0.72 ± 0.22  
    Week 52      
T/V 89 (74.8) 7.99 ± 2.51 7.83 ± 3.11 −0.11 ± 0.36 <0.001 
L/H 94 (77.7) 7.75 ± 2.41 9.15 ± 4.08 1.49 ± 0.35  
    Study end      
T/V 108 (90.8) 7.98 ± 2.44 7.74 ± 2.98 −0.21 ± 0.36 <0.001 
L/H 107 (88.4) 7.89 ± 2.50 9.32 ± 4.52 1.44 ± 0.36  
Absolute change in blood insulin (pmol/l) measured at 2 h during an OGTT      
    Week 12      
T/V 100 675.91 ± 405.27 706.40 ± 438.22 33.92 ± 42.48 0.037 
L/H 99 631.62 ± 450.20 773.52 ± 510.17 147.67 ± 41.18  
    Week 52      
T/V 83 639.01 ± 382.51 585.77 ± 447.92 −52.14 ± 44.79 0.014 
L/H 86 648.47 ± 460.15 718.29 ± 511.98 90.15 ± 42.88  
    Study end      
T/V 105 672.02 ± 397.71 633.09 ± 456.05 −30.13 ± 38.38 0.025 
L/H 102 633.51 ± 444.43 711.34 ± 497.01 84.86 ± 38.33  
Absolute change in fasting blood glucose (mmol/l) at 0 min during an OGTT      
    Week 12      
T/V 104 5.90 ± 0.89 5.71 ± 0.69 −0.07 ± 0.08 <0.001 
L/H 107 5.77 ± 0.69 6.08 ± 0.89 0.33 ± 0.08  
    Week 52      
T/V 89 5.90 ± 0.87 6.26 ± 1.17 0.36 ± 0.23 0.336 
L/H 95 5.80 ± 0.71 6.46 ± 2.55 0.65 ± 0.22  
    Study end      
T/V 110 5.88 ± 0.88 6.11 ± 1.12 0.24 ± 0.23 0.087 
L/H 110 5.77 ± 0.68 6.57 ± 2.95 0.76 ± 0.22  
Absolute change in A1C (%)      
    Week 12      
T/V 109 5.8 ± 0.6 5.8 ± 0.5 0.0 ± 0.0 <0.001 
L/H 112 5.7 ± 0.5 6.0 ± 0.8 0.3 ± 0.0  
    Week 52      
T/V 94 5.8 ± 0.6 5.9 ± 0.6 0.2 ± 0.1 0.055 
L/H 97 5.7 ± 0.4 6.1 ± 0.9 0.3 ± 0.1  
    Study end      
T/V 115 5.8 ± 0.6 5.9 ± 0.6 0.1 ± 0.1 0.027 
L/H 115 5.7 ± 0.5 6.2 ± 1.4 0.4 ± 0.1  

For all study end rows, mean (±SD) 46.9 ± 13.5 weeks.

*

Adjusted for center and baseline.

†

Primary outcome is the absolute change in blood glucose (mmol/l) measured at 2 h during an OGTT.

View Large
View Original Article
DIABETES CARE
2007